Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Mise à jour : Il y a 4 ans
Référence : NCT02050594

Femme et Homme

Extrait

The primary objective of the protocol is to identify and describe observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study period


Critère d'inclusion

  • Melanoma

Liens